Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTaking phentermine and semaglutide together is not a combination that UK-licensed guidance or approved prescribing practice supports. Phentermine is not licensed for weight management in the UK, which means the question of combining it with semaglutide — the active ingredient in Wegovy — simply does not arise within a legitimate clinical pathway here. If you have come across this combination discussed online, it almost certainly reflects US prescribing practice, where phentermine has been used for decades. In the UK, both Wegovy and Mounjaro are prescription-only medicines and every course must be assessed and authorised by a registered prescriber before a single dose is dispensed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Phentermine is a sympathomimetic stimulant that was widely prescribed for weight loss from the 1950s onwards. The European Medicines Agency withdrew marketing authorisations across EU member states in 2000 over cardiovascular safety concerns, and the UK followed suit. It is not currently licensed as a standalone weight-loss medicine in Great Britain, you cannot obtain it lawfully from a UK pharmacy, whether online or on the high street. That single fact largely settles the question. Combining phentermine with semaglutide is not a pathway that any UK prescriber can offer you through legitimate channels.
The US position is different. The FDA approves phentermine as a short-term weight-loss aid and also licences a fixed-dose combination of phentermine and topiramate (brand name Qsymia). Some US clinics have explored adding semaglutide to a phentermine regimen, and that is where most of the online discussion originates. The semaglutide overview on this site covers the UK-licensed context in full if you want to understand the medicine's approved use here.
For UK readers, the practical answer is that neither the medicine nor the combination is accessible through a legitimate domestic route. The relevant question for most people reading this is: which licensed UK treatment, or combination of licensed UK treatments, suits my situation? That is a clinical conversation, not one this page can resolve for you individually.
Even in countries where phentermine is available, the combination with a GLP-1 receptor agonist like semaglutide draws careful prescriber scrutiny. Phentermine raises heart rate and blood pressure as part of its mechanism. Semaglutide, meanwhile, has its own cardiovascular monitoring requirements and is known to cause nausea, vomiting and dehydration during the titration phase, side effects that are more clinically significant if heart rate is already elevated by a stimulant.
The NHS medicines page for semaglutide sets out the side-effect profile clearly: gastrointestinal effects, headache, dizziness and fatigue are among the most commonly reported. Adding a stimulant into that picture introduces overlapping cardiovascular signals that a prescriber would need to monitor closely. Psychiatric effects (anxiety, insomnia, irritability) are associated with stimulants, and GLP-1 medicines carry their own guidance on monitoring mood. Taken individually, both medicines have manageable risk profiles when properly supervised. Together, the monitoring burden increases substantially.
There is also an interaction concern around gastric emptying. Semaglutide slows the rate at which the stomach empties, which can affect the absorption timing of other oral medicines. This is one reason the metformin and Wegovy combination, for example, requires prescriber discussion: timing and absorption both matter. A stimulant taken alongside a medicine that delays gastric emptying may reach peak plasma concentrations at unpredictable times, which matters for dosing safety.
The reality of UK private weight management is that semaglutide is used as a standalone medicine, not layered with unlicensed stimulants. Where clinicians consider combinations at all, they tend to involve other licensed or closely studied agents. Questions about semaglutide and liraglutide together come up occasionally, though the answer there is equally straightforward, two GLP-1 receptor agonists are not prescribed in parallel.
Metformin is sometimes co-prescribed with GLP-1 medicines for people with type 2 diabetes or metabolic syndrome, which is why we have covered that combination separately. Orlistat, which blocks fat absorption rather than acting on appetite centrally, is another licenced option that a prescriber might assess alongside GLP-1 therapy in specific circumstances. None of these combinations should be self-initiated. Every dose change, every addition to a regimen, goes back to the prescriber for review.
If you are curious about how treatment costs are structured when taking Wegovy through a private clinic, the cost page gives an honest breakdown. For context on how widely semaglutide is now used (and why clinical oversight matters at scale) the page on semaglutide prescribing numbers covers the latest UK and global figures.
Yes, without question. If you have previously taken phentermine (sourced abroad, through an online seller, or in another country) your prescribing team needs to know. This is not about disclosure for its own sake. Phentermine has a half-life of around 19–24 hours and cardiovascular effects that persist after a dose; washout matters. More broadly, a prescriber building a picture of your medical history needs to understand every appetite-affecting medicine you have taken, including supplements marketed as fat burners that may contain stimulant compounds.
This extends to anything you are currently taking. The clinical assessment at a regulated UK pharmacy is not a formality. At nume, a GPhC-registered Independent Prescriber (a real clinician, not a decision tree) reads your answers and your declared medications before approving treatment. That review happens the same day you submit your consultation. If something in your history needs clarification, the prescriber contacts you directly; they do not simply approve or decline on algorithm logic. Our clinical team and the standards behind our practice are described on the about page if you want to understand the governance structure.
The short version: be transparent. A question like this one (can you take phentermine and semaglutide together) is exactly the kind of thing to raise in a free consultation rather than piece together from forum posts, and if you are also wondering whether you can take Ozempic and semaglutide together, that is another question the prescriber can address for your specific situation. You can start your free consultation and ask directly; the prescriber's job is to answer it for your specific situation, not a hypothetical one.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.